

Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes after Intensive Statin Treatment: The YELLOW II study

Annapoorna S. Kini, MD, Yuliya Vengrenyuk, PhD, Khader Shameer, PhD, Akiko Maehara, MD, Meerarani Purushothaman, PhD, Takahiro Yoshimura, MD, Mitsuaki Matsumura, BS, Melissa Aquino, MS, Nezam Haider, PhD, Kipp W. Johnson, BS, Ben Readhead, MBBS, Brian A. Kidd, PhD, Jonathan E. Feig, MD, PhD, Prakash Krishnan, MD, Joseph Sweeny, MD, Milind Mahajan, PhD, Pedro Moreno, MD, Roxana Mehran, MD, Jason C. Kovacic, MD, PhD, Usman Baber, MD, Joel T. Dudley, PhD, Jagat Narula, MD, PhD, Samin Sharma, MD

PII: S0735-1097(16)36776-6

DOI: [10.1016/j.jacc.2016.10.029](https://doi.org/10.1016/j.jacc.2016.10.029)

Reference: JAC 23134

To appear in: *Journal of the American College of Cardiology*

Received Date: 18 October 2016

Revised Date: 24 October 2016

Accepted Date: 24 October 2016

Please cite this article as: Kini AS, Vengrenyuk Y, Shameer K, Maehara A, Purushothaman M, Yoshimura T, Matsumura M, Aquino M, Haider N, Johnson KW, Readhead B, Kidd BA, Feig JE, Krishnan P, Sweeny J, Mahajan M, Moreno P, Mehran R, Kovacic JC, Baber U, Dudley JT, Narula J, Sharma S, Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes after Intensive Statin Treatment: The YELLOW II study, *Journal of the American College of Cardiology* (2016), doi: 10.1016/j.jacc.2016.10.029.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes after Intensive Statin Treatment: The YELLOW II study

Annapoorna S Kini MD¹, Yuliya Vengrenyuk PhD¹, Khader Shameer PhD², Akiko Maehara MD³, Meerarani Purushothaman PhD¹, Takahiro Yoshimura MD¹, Mitsuaki Matsumura BS³, Melissa Aquino MS¹, Nezam Haider PhD¹, Kipp W Johnson BS², Ben Readhead MBBS², Brian A Kidd PhD², Jonathan E Feig MD, PhD¹, Prakash Krishnan MD¹, Joseph Sweeny MD¹, Mahajan, Milind PhD¹, Pedro Moreno MD¹, Roxana Mehran MD¹, Jason C Kovacic MD, PhD¹, Usman Baber MD¹, Joel T Dudley PhD², Jagat Narula MD, PhD¹, Samin Sharma MD¹

¹Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai, New York, New York

²Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York

³Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York

Running title: OCT cap thickness and cholesterol efflux after statin therapy

Relationships with industry: This research was conducted with support from the Investigator-Sponsored Study Program of AstraZeneca, partial support from Infraredx and Mount Sinai catheterization laboratory endowment funds allocated to Dr. Kini. Dr. Jason Kovacic (a Co-Investigator in this study) received financial compensation as a lecturer for AstraZeneca in 2014 (the study co-sponsor and manufacturer of the drug rosuvastatin being used in the study). Dr. George Dangas' (a Co-Investigator on this study) spouse is Dr. Roxana Mehran, the Director of Interventional Cardiovascular Research and Clinical Trials. Dr. Mehran received financial compensation as a consultant and lecturer for AstraZeneca in 2014. Dr. Pedro Moreno (a Co-Investigator on this study) is a co-Founder of InfraReDx, Inc. and is named under the first patent for LipiScanTM NIR Coronary Imaging System (near infrared spectroscopy, also known as NIRS) marketed by InfraReDx. NIRS imaging technology was utilized in this study intervention. Dr. Moreno also owns equity in InfraReDx in the form of stock options. InfraReDx is a privately funded medical device company that is the only company with an intravascular imaging system that is FDA-approved for the detection of lipid core plaques. Dr. Moreno also receives financial compensation as a speaker for AstraZeneca (the study sponsor and manufacturer of the study drug rosuvastatin).

Acknowledgements: This research was conducted with support from the Investigator-Sponsored Study Program of AstraZeneca, partial support from Infraredx and Mount Sinai catheterization laboratory endowment funds allocated to Dr. Kini.

Corresponding Author:

Annapoorna Kini, MD
One Gustave L. Levy Place, Box 1030
New York, New York 10029
Telephone: 212-241-4181
Fax: 212-534-2845
E-mail: annapoorna.kini@m MountSinai.org

Download English Version:

<https://daneshyari.com/en/article/5608557>

Download Persian Version:

<https://daneshyari.com/article/5608557>

[Daneshyari.com](https://daneshyari.com)